Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Recurrence 1Medulloblastoma 1Carcinoma, Basal Cell 1

Interventions

Temozolomide 6sonidegib 4Irinotecan 3Topotecan 2LY2940680 2Cyclophosphamide 2ribociclib 1pomalidomide 1palbociclib 1omburtamab I-131 1exatecan 1entrectinib 1dinutuximab 1bempegaldesleukin 1abemaciclib 1TB-403 1Pemetrexed 1ONC206 1Nivolumab 1NVP-LEQ506 1Granulocyte-Macrophage Colony-Stimulating Factor 1Filgrastim 1Fentanyl 1Etoposide 1CLR1404 1Biological Factors 190Y-octreotide, DOTA-Tyr(3)- 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Medulloblastoma × NVP-LEQ506 × Clear all
NCT01106508 2020-12-17

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
57 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡